drugset / Trial / NCT05344625

Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

NCT05344625

Phase 0 Withdrawn Northwell Health
NaSingle-groupOpen-labelTreatment

Summary

The present study will investigate if ketamine-assisted psychotherapy during palliative radiation therapy is safe, feasible, and effective at reducing psychological distress.

Timeline

Start
2023-10-31
Primary completion
2024-03-15
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 1 mg/kg Intramuscular
Subject Ketamine Small molecule 60 mg Intramuscular